Intravenous (IV) fibrinolytic therapy, a recent area of research, has a great deal of applicability in emergency medicine. We report our experience with 30 @entity1 treated with this method. Thirty consecutive @entity1 in the early stages of @entity583 ( @entity583 ) were assigned to receive high-dose IV streptokinase, 1.5 million units over a 30-minute period. @entity1 presented to the treating hospital at a mean time of 1.21 +/- 1.08 hours, and treatment commenced at a mean time of 2.77 +/- 1.31 hours after the onset of symptoms. Using standard clinical criteria, 86.7% (n = 26) of the @entity1 reperfused initially. Two, however, reoccluded within the first 48 hours, and their clinical symptoms of @entity583 reappeared. By clinical observation 80% (n = 24) of the @entity1 reperfused, and myocardial salvage was observed. Twenty-four @entity1 with clinical reperfusion and one additional @entity1 had patency of the affected artery, yielding a reperfusion rate of 83.3% (n = 25) as judged by angiography within one week of @entity583 . Both @entity1 who had reoccluded clinically also were found to be occluded on angiography. Clinical and angiographic methods yield very similar results for the judgment of reperfusion (80% vs 83%, respectively, with no significant difference, P not significant). The results of our study tend to confirm the efficacy of IV streptokinase as a valuable management tool for early @entity583 .

Intravenous streptokinase in acute XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity583 :: ('MESH:D009203', 'Disease') :: ['AMI', 'myocardial infarction', 'acute evolving myocardial infarction']
@entity583 :: (MESH:D009203,Disease) :: ['myocardial infarction']
